Maererano neChiziviso cheNational Medical Products Administration's No. 103 of 2024, kupinza, kutengesa, uye kushandiswa kweUCB Pharma SA Levetiracetam Injection Concentrate kwakatangwa zvakare.

Zvichienderana nemhedzisiro yekuongorora kusiri kwenzvimbo, National Medical Products Administration (NMPA) yakapa Chiziviso Nha. 67 musi wa22 Nyamavhuvhu 2022, ichifunga kumisa kupinza, kutengesa, uye kushandisa UCB Pharma SA's Levetiracetam Injection Concentrate Solution (yekutanga zita rekunyoresa nhamba: H45mgl0170: H45mgl0170 Keppra).

Mushure mekunge UCB Pharma SA yapedza zviito zvekugadzirisa zvaidiwa, vakaendesa chikumbiro uye zvine chekuita nekugadzirisa chiitiko mushumo kuNMPA kuti vatangezve kupinza, kutengesa, uye kushandiswa kwechigadzirwa. Zvichitevera ongororo yehunyanzvi, NMPA yakasimbisa kuti nyaya dzakaonekwa panguva yekuongorora kunze kwenyika zvisiri zvenzvimbo dzakagadziriswa.

Zvinoenderana ne "Drug Administration Law yePeople's Republic of China" uye "Mitemo yeOverseas Inspection of Drugs and Medical Devices," NMPA yafunga kutangazve kupinza, kutengesa, uye kushandiswa kweLevetiracetam Injection Concentrate Solution (nhamba yekunyoresa ikozvino: National Drug Approval HJ20170341, zita rakabudiswa ne50mgrar: 50ml) Pharma SA kubva Chikumi 4, 2024.

Pakuburitswa kwechiziviso ichi, madhipatimendi anoona nezvezvinodhaka uye manejimendi pachiteshi chekutengesa zvinodhaka achapa zvitupa zvemvumo kubva kunze kwechigadzirwa.